Frequency of AML 1 mutations in the specific types of hematopoietic disease
. | . | . | AML 1 mutation . | . | . | ||
|---|---|---|---|---|---|---|---|
| Diagnosis . | History . | No. cases . | Total, no. (%) . | N-terminal, no. (%) . | C-terminal, no. (%) . | ||
| RAEB, RAEBt, and AML following MDS (MDS/AML) | |||||||
| RAEB | |||||||
| Sporadic | 36 | 5 (13.9) | 3 (8.3) | 2 (5.6) | |||
| Secondary | 5 | 1 (20.0) | 1 (20.0) | 0 (0.0) | |||
| Total | 41 | 6 (14.6) | 4 (9.8) | 2 (4.9) | |||
| RAEBt | |||||||
| Sporadic | 23 | 6 (26.1) | 3 (13.0) | 3 (13.0) | |||
| Secondary | 12 | 9 (75.0) | 8 (66.7) | 1 (8.3) | |||
| Total | 35 | 15 (42.9) | 11 (31.4) | 4 (11.4) | |||
| AML following MDS | |||||||
| Sporadic | 29 | 4 (13.8) | 1 (3.4) | 3 (10.3) | |||
| Secondary | 5 | 1 (20.0) | 1 (20.0) | 0 (0.0) | |||
| Total | 34 | 5 (14.7) | 2 (5.8) | 3 (8.8) | |||
| Total MDS/AML | |||||||
| Sporadic | 88 | 15 (17.0) | 7 (8.0) | 8 (9.1) | |||
| Secondary | 22 | 11 (50.0) | 10 (45.5) | 1 (4.5) | |||
| Total | 110 | 26 (23.6) | 17 (15.4) | 9 (8.2) | |||
| AML without antecedent MDS (de novo AML) | |||||||
| AML without antecedent MDS | |||||||
| Sporadic | 95 | 1 (1.1) | 1 (1.1) | 0 (0.0) | |||
| Secondary | 20 | 4 (20.0) | 4 (20.0) | 0 (0.0) | |||
| Total | 115 | 5 (4.3) | 5 (4.3) | 0 (0.0) | |||
| Others | |||||||
| RA/RARS | Total | 45 | 1 (2.2) | 1 (2.2) | 0 (0.0) | ||
| CMMoL | Total | 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| MPD | Total | 51 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| ALL | Total | 28 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| CML/CML-BC | Total | 23 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
. | . | . | AML 1 mutation . | . | . | ||
|---|---|---|---|---|---|---|---|
| Diagnosis . | History . | No. cases . | Total, no. (%) . | N-terminal, no. (%) . | C-terminal, no. (%) . | ||
| RAEB, RAEBt, and AML following MDS (MDS/AML) | |||||||
| RAEB | |||||||
| Sporadic | 36 | 5 (13.9) | 3 (8.3) | 2 (5.6) | |||
| Secondary | 5 | 1 (20.0) | 1 (20.0) | 0 (0.0) | |||
| Total | 41 | 6 (14.6) | 4 (9.8) | 2 (4.9) | |||
| RAEBt | |||||||
| Sporadic | 23 | 6 (26.1) | 3 (13.0) | 3 (13.0) | |||
| Secondary | 12 | 9 (75.0) | 8 (66.7) | 1 (8.3) | |||
| Total | 35 | 15 (42.9) | 11 (31.4) | 4 (11.4) | |||
| AML following MDS | |||||||
| Sporadic | 29 | 4 (13.8) | 1 (3.4) | 3 (10.3) | |||
| Secondary | 5 | 1 (20.0) | 1 (20.0) | 0 (0.0) | |||
| Total | 34 | 5 (14.7) | 2 (5.8) | 3 (8.8) | |||
| Total MDS/AML | |||||||
| Sporadic | 88 | 15 (17.0) | 7 (8.0) | 8 (9.1) | |||
| Secondary | 22 | 11 (50.0) | 10 (45.5) | 1 (4.5) | |||
| Total | 110 | 26 (23.6) | 17 (15.4) | 9 (8.2) | |||
| AML without antecedent MDS (de novo AML) | |||||||
| AML without antecedent MDS | |||||||
| Sporadic | 95 | 1 (1.1) | 1 (1.1) | 0 (0.0) | |||
| Secondary | 20 | 4 (20.0) | 4 (20.0) | 0 (0.0) | |||
| Total | 115 | 5 (4.3) | 5 (4.3) | 0 (0.0) | |||
| Others | |||||||
| RA/RARS | Total | 45 | 1 (2.2) | 1 (2.2) | 0 (0.0) | ||
| CMMoL | Total | 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| MPD | Total | 51 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| ALL | Total | 28 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| CML/CML-BC | Total | 23 | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||